



Department  
Radiation

Published on *UCSF Department of Radiation Oncology* (<http://radonc.ucsf.edu>)

[Home](#) > [Our Team](#) > [Medical Faculty](#) > [Felix Feng](#)

---

## Felix Feng

---

**Felix Y. Feng, M.D.**

**Vice Chair for Faculty Development  
and Translational Research,**

**Department of Radiation Oncology**

**Associate Professor of Radiation Oncology,  
Urology, and Medicine**



University of California, San Francisco  
Helen Diller Family Cancer Research Building  
Box 3110, 1450 Third Street, Room 383  
San Francisco, CA 94158  
Phone: 415 502-7222  
Fax: 415 476-7370

**Research Website** <sup>[1]</sup>

Make A Gift  
Support Our Research

<sup>[2]</sup>

## Professional Focus

Dr. Felix Feng is a radiation oncology leader in translational research. The primary aim of Dr. Feng's research program is to individualize therapy for patients with aggressive prostate cancer, by identifying determinants of treatment resistance and developing strategies to overcome this resistance.

To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers.

Dr. Feng serves on the National Cancer Institute Genitourinary Cancer Steering Committee, which oversees and evaluates clinical trials proposed by all national clinical trials cooperative groups. He also serves as Chair of the Biology Scientific Track for the American Society of Radiation Oncology, and as Chair of the Genitourinary Translational Research Program for the RTOG/NRG national cooperative group.

## Education

1994-1998	Stanford University	BS	Distinction and Honors in Biological Sciences
1998-2002	Washington University School of Medicine	MD	
2002-2003	Saint Joseph Mercy Hospital, Ypsilanti, Michigan	Internship	Internal Medicine
2003-2005	University of Michigan Medical Center, Ann Arbor, Department of Radiology	Resident	Radiology
2005-2006	University of Michigan Medical Center, Ann Arbor, Department of Radiation Oncology	Postdoctoral Research Fellow	Radiation Biology
2006-2010	University of Michigan Medical Center, Ann Arbor, Department of Radiation Oncology	Resident	Radiation Oncology
2009-2010	University of Michigan Medical Center, Ann Arbor, Department of Radiation Oncology	Chief Resident	Radiation Oncology

## Professional Experience

<b>PRINCIPAL POSITIONS HELD</b>			
2013-2016	University of Michigan, Ann Arbor	Director, Division of Translational Genomics	Radiation Oncology
2010-2016	University of Michigan, Ann Arbor	Assistant Professor	Radiation Oncology
2016-present	University of California, San Francisco	Vice Chair for Faculty Development and Translational Research	Radiation Oncology
2016-present	University of California, San Francisco	Associate Professor of Radiation Oncology, Urology, and Medicine	Radiation Oncology and Urology
<b>OTHER POSITIONS HELD CONCURRENTLY</b>			
2010-2016	The University of Michigan Comprehensive Cancer Center Primary: Prostate Cancer Program Secondary: Radiation Sciences	Core Member	Radiation Oncology
2010-2016	Ann Arbor Veteran's Health System, Ann Arbor, Michigan	Assistant Professor	Radiation Oncology
2011-2011	Ann Arbor Veteran's Health System, Ann Arbor, Michigan	Acting Chief	Radiation Oncology
2011-2016	University of Michigan	Chair	Genitourinary Translational Research Program for the NRG/RTOG Cooperative Trials Group
2011-2016	Allegiance Health System, Jackson, Michigan	Active Staff	Radiation Oncology
2011-2016	Ingham Regional Medical Center, Lansing, Michigan	Active Staff	Radiation Oncology
2011-2016	Providence Hospital, Southfield, Michigan	Active Staff	Radiation Oncology

2015-2016	University of Michigan, Ann Arbor	Associate Chair for Laboratory Research	Radiation Oncology
2010-present	NRG/RTOG Cooperative Group	Leader	Genitourinary Cancer Translational Research Program

## Awards & Honors

1994	President's Scholar for Academic Achievement (for scholastic achievement at Stanford University)
1995	President's Award for Academic Excellence (for scholastic achievement at Stanford University)
1997	Barry M. Goldwater Fellowship for Excellence in Mathematics, Science, and Engineering (national collegiate award/grant for outstanding basic science research)
1998	Dr. Philip Majerus Distinguished Alumni Scholarship 1998-2002 (full-tuition, four-year merit scholarship at the Washington University School of Medicine, awarded to three students per class)
1999	Washington University Research Award (best summer research project among med students)
2000	American College of Physicians Award for Excellence in Physical Diagnosis
2000	Best Presentation, Midwest Association of Plastic Surgeons Conference
2000	McLaughlin Award, National Student Research Forum (for best presentation in immunology)
2002	Dr. Richard S. Brookings Medical School Prize (awarded for the highest achievement in research among the graduating medical school class)
2002	Missouri State Medical Association Award (for scholastic achievement in medical studies)
2006	Merit award, Translational Research Symposium, ASTRO
2006	First place presentation, Michigan Society of Therapeutic Radiation Oncology (MSTRO) Resident Research Competition
2008	ASTRO Resident Clinical Research Award (for the best abstract submitted by a resident physician to the annual meeting)
2009	Travel grant, Radiation Therapy Oncology Group annual meeting
2009	Resident Scholarship for American Brachytherapy Society/Seattle Prostate Brachytherapy course
2010	Radiological Society of North America Roentgen Resident/Fellow Research Award
2012	American Society of Radiation Oncology Basic Science Award (for the best basic science abstract submitted to the annual meeting of this group)

2014	Teacher of the Year, Radiobiology, Department of Radiation Oncology, University of Michigan
2016	American Society of Radiation Oncology Clinical Science Award (for the best clinical science abstract submitted to the annual meeting of this group)

Recent Significant Publications :

**Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.** Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY. *JAMA Oncol.* 2016 Jan 7;1-10. PMID: 26746117

**DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.** Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE. *Cancer Cell.* 2015 Jul 13;28(1):97-113. PMID: 26175416

**Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.** Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. *Int J Radiat Oncol Biol Phys.* 2015;93(4):828-35. doi: 10.1016/j.ijrobp.2015.07.2281. PubMed PMID: 26530751.

**Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.** Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. *Eur Urol.* 2015 Oct;68(4):555-67. PMID: 25964175

**The landscape of long noncoding RNAs in the human transcriptome.** Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. *Nature Genetics.* 2015 Mar;47(3):199-208.

**Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.** Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. *Nature.* 2014;510(7504):278-82.

**A Tissue Biomarker-Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02.** Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. *Clin Cancer Research.* 2014 Dec 15;20(24):6379-88.

**RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.**

Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY. *Lancet Oncol.* 2014 Dec;15(13):1469-80. PMID:25456366

**The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc.** Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, Lawrence TS, Chinnaiyan AM, Feng FY. *Neoplasia.* 2014 Nov 20;16(11):900-8.

**PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.** Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. *Cancer Res.* 2014 Mar 15;74(6):1651-60. PMID: 24473064

\*/

UCSF Main Site

© 2015 The Regents of the University of California

---

**Source URL:** <http://radonc.ucsf.edu/felix-feng>

**Links**

[1] <http://fenglaboratory.com>

[2] <http://radonc.ucsf.edu/make-gift>